Improvement and Evaluation of Adverse Drug Reactions Monitoring System in Our Hospital

Chinese Journal of Pharmacovigilance ›› 2016, Vol. 13 ›› Issue (2): 87-89.

• Orignal Article • Previous Articles Next Articles

Improvement and Evaluation of Adverse Drug Reactions Monitoring System in Our Hospital

XIA Yun¹, LU Yi-yan², FAN Bei-bei¹, CAO Shan¹, QU Hong^{1, *}

1 Department of Pharmacy, Shanghai Baoshan District Hospital of Integrated Traditional and Western Medicine, Shanghai 201900, China;
2 Shanghai Baoshan Branch of Food and Drug Administration, Shanghai 200439, China

Received:2016-03-14 Revised:2016-03-14 Online:2016-02-08 Published:2016-03-14

Abstract

Abstract: ObjectiveTo improve the ADR monitoring system and ensure this system to play an important role in drug safe use. MethodsThrough training and changing the mode of reward, the reporters’ enthusiasm was improved. Through clarifying responsibilities, clinical pharmacists played the guiding role in ADR monitoring. By developing the ADR monitoring platform the reporting process was simplified. ResultsThe quantity and quality of ADR reports, the percentage of new serious ADR reports and the effect of ADR early warning and intervention measures were enhanced greatly after ADR monitoring system had been improved. ConclusionThe methods of improving our hospital ADR monitoring system are correct and can provide a reference for other medical institutions.

Key words: Key Words: ADR monitoring system, improvement, evaluation

CLC Number:

R994.11

XIA Yun, LU Yi-yan, FAN Bei-bei, CAO Shan, QU Hong. Improvement and Evaluation of Adverse Drug Reactions Monitoring System in Our Hospital[J]. Chinese Journal of Pharmacovigilance, 2016, 13(2): 87-89.

[1]	JIA Yinyin, ZHANG Caishu, ZHOU Ying, LIU Li, GENG Ying, WEI Ningyi, NIU Sijing, CHEN Hua, XU Hui. Evaluation methods for aerodynamic particle size distribution of fine particles in inhaled products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 141-146.
[2]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[3]	FANG Zhie, LI Chengxian, BAI Zhaofang, ZHAO Xu, WANG Jiabo, XIAO Xiaohe. Investigation of objectivity in the relationship between aristolochic acid and hepatocellular carcinoma [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 20-24.
[4]	ZHANG Qi, CHEN Min, ZHANG Shiqing. Conditional approval of medical devices in the United States and enlightenment [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1007-1010.
[5]	CHEN Jie, QIN Kan. Evaluation of individualized parenteral nutrition delivery [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 812-816.
[6]	NIE Xiaolu, TANG Shaowen, YU Jinyang, SONG Haibo, FU Zhu, SUN Feng. Interpretations of reporting recommendations intended for pharmaceutical risk minimization evaluation studies(RIMES) statement [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 524-529.
[7]	YUE Xiaolin, LU Song, ZHANG Lan. Research in the construction of comprehensive evaluation systems of drugs in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 530-535.
[8]	LIU Huan, YUAN Hui, YIN Jingjing, LIU Mengya, QIN Xiujun, LI Jianguo. General toxicology of Yiya Jianpi jel among juvenile animals [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 416-422.
[9]	LIU Jing, LIU Yan, ZHENG Xiaowei, WANG Qi, HE Fengyan, WANG Feifei, WANG Yadan, HE Yi, NIE Lixing, HU Xiaoru, DAI Zhong, MA Shuangcheng. Quality analysis of Guci tablets based on national drug evaluation sampling [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 292-295.
[10]	WANG Yadan, YAN Jiangong, CHEN Minghui, PANG Yu, DAI Zhong, MA Shuangcheng. UPLC fingerprints of tripterygium glycosides tablets from different manufacturers [J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 146-151.
[11]	WANG Jiaqing, WANG Qi, ZHANG Dongjie, MEI Shenghui, NING Xiao. Uncertainty evaluation on the determination of norvancomycin in human cerebrospinal fluid by UPLC-MS/MS [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1346-1350.
[12]	KE Bingbing, LI Yan, WANG Pinghui, XU Xiaoling, SHEN Jiate, LYU Xiaojun. Evaluation of anaphylactoid reactions induced by human immunoglobulin for intravenous injection(pH 4.0) based on mouse auricular blue staining experiments [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1357-1361.
[13]	WANG Zhao, LIU Yue, ZAN Ke, LI Hailiang, JIN Hongyu, MA Shuangcheng. Preliminary study on extraction technology of tea extract used for Xinnaojian preparation [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1362-1367.
[14]	GUAN Haoyue, LIU Nian, QI Mengjie, SUN Baihao, LIU Xuejing, HU Yang, NIU Jianzhao. Quality analysis of donepezil hydrochloride tablet [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1375-1381.
[15]	YIN Jinjun, WANG Shuwei, SHAO Jiangchao, WANG Bing. Drug use evaluation of bevacizumab injection based on weighted TOPSIS method [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1421-1426.

Improvement and Evaluation of Adverse Drug Reactions Monitoring System in Our Hospital

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics